Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22905725 | 0.97 | CYP1A2 (0.37) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL22905481 | 0.83 | POLB (0.37) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL24177880 | 0.71 | POLB (0.40) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL29225055 | 0.71 | POLB (0.43) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL28725429 | 0.71 | POLB (0.40) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL10426958 | 0.71 | TDP1 (0.53) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL22905442 | 0.68 | NLRP3 (0.60) | — | |
| SCHEMBL9803087 | 0.68 | CYP1A2 (0.51) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL5456883 | 0.68 | KMT2A (0.39) | POLBKMT2ACYP1A2CYP2C19RECQL | |
| SCHEMBL23121598 | 0.68 | KMT2A (0.39) | POLBKMT2ACYP1A2CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555571-B | N- ((1, 2,3,5,6, 7-hexahydro-s-indacen-4-yl) carbamoyl) -4,5,6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives as NLRP3 modulators | 祖玛珍生物科学有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20220396559-A1 | N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD | 2022-12-15 | — | — | US | disclosed |
| CN-114555571-A | N- ((1,2,3,5,6, 7-hexahydro-s-indacen-4-yl) carbamoyl) -4,5,6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of Multiple Sclerosis (MS) | 祖玛珍生物科学有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021009566-A1 | N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396559-A1 | N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | GLS2, FFAR3, FABP1 | POLB 4535/4885KMT2A 4453/4885CYP1A2 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.